It is also to highlight that the NLRP3 inflammasome in macrophages can be activated by a multitude of viruses and viral proteins, such as the severe acute respiratory syndrome coronavirus (SARS-CoV) viroporin [56] and that the Italian agency of pharmaceuticals (AIFA) recently approved the use of canakinumab for the treatment of patients affected by Coronavirus disease-19 (COVID-19) (aifa.gov.it). The gene discussed is NLRP3; the disease is COVID-19.